SCHEMBL7180445

SCHEMBL7180445

Cc1cc(OC(C)C)ccc1PC(=O)c1c(C)cc(C)c(C)c1C.[LiH]

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
TDP1 Q9NUW8 2/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 3/20 0.35
HPGD P15428 2/20 0.35
GAA P10253 2/20 0.35
LMNA P02545 1/20 0.35
PARP10 Q53GL7 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ACACB O00763 2/20 0.34
ACACA Q13085 2/20 0.34
TSPO P30536 1/20 0.34
MAPT P10636 3/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33
GLA P06280 1/20 0.33
BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177965 0.90 ALDH1A1 (0.35) ALDH1A1TDP1POLBKMT2AKDM4E
SCHEMBL7181198 0.88 SMN1; SMN2 (0.36) TDP1ACACBMAPTFFAR4
Lithium SCHEMBL7177970 0.87 ALDH1A1 (0.35) ALDH1A1TDP1POLBKMT2AKDM4E
Lithium SCHEMBL7183847 0.87 TDP1 (0.35) TDP1LMNAMAPT
SCHEMBL7182015 0.86 FFAR4 (0.41) ALDH1A1TDP1POLBKMT2AKDM4E
SCHEMBL7178301 0.86 CYP3A4 (0.37) ALDH1A1POLBKMT2AKDM4EHPGD
SCHEMBL7188478 0.86 XDH (0.39) ALDH1A1POLBKMT2AKDM4EHPGD
SCHEMBL7177720 0.85 POLB (0.40) ALDH1A1TDP1POLBKMT2AKDM4E
SCHEMBL7186834 0.84 ALDH1A1 (0.39) ALDH1A1TDP1POLBKMT2AKDM4E
Lithium SCHEMBL7189179 0.83 SMN1; SMN2 (0.33) TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885TDP1 4234/4885POLB 2322/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885TDP1 4275/4885POLB 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.